Your browser is no longer supported. Please, upgrade your browser.
Settings
EDIT Editas Medicine, Inc. daily Stock Chart
EDIT [NASD]
Editas Medicine, Inc.
Index- P/E- EPS (ttm)-2.34 Insider Own2.50% Shs Outstand47.65M Perf Week1.22%
Market Cap1.23B Forward P/E- EPS next Y-3.08 Insider Trans-6.14% Shs Float47.14M Perf Month6.97%
Income-110.00M PEG- EPS next Q-0.63 Inst Own79.80% Short Float16.80% Perf Quarter-1.56%
Sales31.90M P/S38.54 EPS this Y21.80% Inst Trans0.16% Short Ratio7.86 Perf Half Y-11.22%
Book/sh4.92 P/B5.24 EPS next Y- ROA-27.40% Target Price46.71 Perf Year-27.02%
Cash/sh7.74 P/C3.33 EPS next 5Y- ROE-46.80% 52W Range17.80 - 41.43 Perf YTD13.41%
Dividend- P/FCF- EPS past 5Y- ROI-42.30% 52W High-37.73% Beta-
Dividend %- Quick Ratio10.40 Sales past 5Y- Gross Margin- 52W Low44.94% ATR1.17
Employees133 Current Ratio10.40 Sales Q/Q64.90% Oper. Margin- RSI (14)54.02 Volatility4.57% 4.74%
OptionableYes Debt/Eq0.14 EPS Q/Q38.60% Profit Margin- Rel Volume0.86 Prev Close25.72
ShortableYes LT Debt/Eq0.14 EarningsFeb 28 AMC Payout- Avg Volume1.01M Price25.80
Recom- SMA201.44% SMA5010.76% SMA200-5.76% Volume865,731 Change0.31%
Apr-12-19Initiated Evercore ISI Outperform
Oct-10-18Initiated Guggenheim Neutral
Sep-21-18Initiated Raymond James Outperform $40
May-15-18Reiterated Chardan Capital Markets Buy $72.50 → $55
Feb-13-18Initiated CLSA Underperform
Jan-23-18Upgrade SunTrust Hold → Buy
Jul-14-17Initiated SunTrust Hold $17
Mar-28-17Initiated Chardan Capital Markets Buy $65
Aug-10-16Upgrade Jefferies Hold → Buy
Jun-02-16Initiated Jefferies Hold
Feb-29-16Initiated Morgan Stanley Equal-Weight $28
Feb-29-16Initiated JP Morgan Neutral
Feb-29-16Initiated JMP Securities Mkt Outperform
Apr-17-19 01:10PM  One-Size-Fits-All CRISPR Lock Could Catapult the Sector Forward GuruFocus.com -5.51%
07:14AM  Vertex, CRISPR's Gene Editing Drug Gets FDA's Fast Track Tag Zacks
Apr-16-19 02:39PM  Bain Capital raising another life sciences fund after $720M debut American City Business Journals
Apr-10-19 02:00PM  3 Top Small-Cap Stocks to Buy in April Motley Fool
Apr-09-19 03:33PM  These Cannabis and China ETFs are Leading the 2019 Rally Investopedia
10:33AM  How Editas Medicine Could Make You Better (and Richer) Motley Fool
09:53AM  5 Stocks in the Age of Miracles Motley Fool
Apr-07-19 02:00PM  3 Top Small-Cap Biotech Stocks for Aggressive Investors Motley Fool
Apr-04-19 03:39PM  Editas (EDIT) Inks Cross Licensing Agreement with BlueRock Zacks
10:33AM  Why Editas Medicine Stock Popped 18.5% in March Motley Fool
Apr-03-19 04:11PM  CRISPR Biotech Inks Deal To Use Stem Cells In Gene-Editing Medicine Investor's Business Daily
09:15AM  Stocks Hold Onto Gains in Quiet Session Zacks
07:00AM  Editas Medicine and BlueRock Therapeutics Enter Strategic Research Collaboration and Cross-Licensing Agreement to Combine Genome Editing and Cell Therapy Platforms GlobeNewswire
Mar-26-19 07:16AM  Better Buy: Editas Medicine vs. Sangamo Therapeutics Motley Fool
07:10AM  Research Report Identifies Spirit Airlines, Integrated Device Technology, Editas Medicine, MACOM Technology Solutions, Taylor Morrison Home, and Brunswick with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Mar-21-19 06:13AM  Should You Buy Bio-Path Stock After 5-Fold Gain? 3 Pros, 3 Cons InvestorPlace
Mar-18-19 12:38PM  What Do Investors Need To Know About Editas Medicine, Inc.s (NASDAQ:EDIT) Earnings Outlook? Simply Wall St.
Mar-12-19 06:00AM  3 Stocks That Could Double Your Money Motley Fool
Mar-07-19 02:47PM  5 Top Gene-Editing Stocks for 2019 Motley Fool
Mar-04-19 06:01PM  Edited Transcript of EDIT earnings conference call or presentation 28-Feb-19 10:00pm GMT Thomson Reuters StreetEvents
09:15AM  S&P Reclaims 2800; NASDAQs Streak Hits 10 Weeks Zacks
Mar-01-19 06:47PM  Why Editas Medicine Stock Soared Today Motley Fool +14.59%
03:20PM  A Specialty Biotech ETF Strengthens on Optimism Over CRISPR Advancements ETF Trends
08:00AM  Editas Medicine Prepares to Make History With EDIT-101 Motley Fool
Feb-28-19 11:22PM  Editas Medicine Inc (EDIT) Q4 2018 Earnings Conference Call Transcript Motley Fool
04:01PM  Editas Medicine Announces Fourth Quarter and Full Year 2018 Results and Update GlobeNewswire
09:00AM  Editas Medicine Supports Global Movement to Raise Awareness on Rare Disease Day® GlobeNewswire
Feb-27-19 09:53AM  The Zacks Analyst Blog Highlights: Spark Therapeutics, Solid Biosciences, REGENXBIO, Editas Medicine and uniQure Zacks
07:19AM  Editas (EDIT) to Report Q4 Earnings: What's in the Cards? Zacks
Feb-26-19 10:54AM  CRISPR Therapeutics Up as Dosing Starts in Thalassemia Study Zacks
08:54AM  5 Gene Therapy Stocks to Enrich Your Portfolio Zacks
Feb-24-19 10:16AM  Better Buy: Editas Medicine vs. Intellia Therapeutics Motley Fool
Feb-21-19 04:02PM  Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2018 Corporate Update and Results GlobeNewswire
Feb-14-19 05:45PM  Editas Medicine (EDIT) Dips More Than Broader Markets: What You Should Know Zacks
12:01PM  Is Moderna a Buy? Motley Fool
Feb-09-19 10:03AM  Should Sangamo's Failure Make CRISPR Investors Nervous? Motley Fool
Feb-08-19 05:45PM  Editas Medicine (EDIT) Outpaces Stock Market Gains: What You Should Know Zacks
Feb-06-19 09:00AM  Editas Medicine Names David Scadden, M.D., to Board of Directors GlobeNewswire
Feb-01-19 05:45PM  Editas Medicine (EDIT) Stock Sinks As Market Gains: What You Should Know Zacks
01:53PM  3 Biotech Stocks That Are Set for a Breakthrough InvestorPlace
Jan-30-19 11:07AM  How Many Insiders Bought Editas Medicine, Inc. (NASDAQ:EDIT) Shares? Simply Wall St.
Jan-25-19 05:45PM  Editas Medicine (EDIT) Gains But Lags Market: What You Should Know Zacks
Jan-24-19 07:35AM  Market Trends Toward New Normal in SeaWorld Entertainment, Rigel Pharmaceuticals, Guidewire Software, Editas Medicine, Jones Energy, and Rexahn Pharmaceuticals Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire +6.12%
Jan-23-19 08:18AM  Better Buy: CRISPR Therapeutics vs. Editas Medicine Motley Fool
07:55AM  Today's Research Reports on Trending Tickers: Editas Medicine and argenx ACCESSWIRE
Jan-22-19 04:28PM  Editas CEO Resigns Sending All 3 CRISPR Stocks Into Free Fall Investor's Business Daily -19.85%
11:38AM  Why Editas Medicine Is Crashing Today Motley Fool
11:06AM  Editas stock down 21% after announcing CEO departure MarketWatch
10:47AM  Gene-Editing Stocks Plunge on Editas CEO Exit, Crispr Downgrade Bloomberg
10:24AM  Editas CEO to step down amid management turnover at gene-editing firm American City Business Journals
09:00AM  Editas Medicine Announces Chief Executive Officer Transition GlobeNewswire
Jan-21-19 11:00AM  Editas Medicine Announces Publication in Nature Medicine of Data Supporting the Development of EDIT-101 to Treat Leber Congenital Amaurosis 10 (LCA10) GlobeNewswire
Jan-18-19 05:45PM  Editas Medicine (EDIT) Stock Sinks As Market Gains: What You Should Know Zacks
12:55PM  4 Gene-Editing Technologies That Could Replace CRISPR Motley Fool
Jan-15-19 07:50AM  Today's Research Reports on Trending Tickers: Exelixis and Editas Medicine ACCESSWIRE +5.64%
Jan-11-19 05:50PM  Editas Medicine (EDIT) Dips More Than Broader Markets: What You Should Know Zacks
Jan-10-19 06:05PM  Here's Why Editas Medicine Lost 16.6% in December Motley Fool
03:36PM  The Best CRISPR Stock Gained 21% in 2018, While The Worst Lost 29% Motley Fool
08:15AM  4 Reasons Editas Medicine's Future Looks Really Bright Motley Fool
Jan-09-19 11:21AM  CRISPR cadre: Check out the 12 Mass. companies exploring gene editing American City Business Journals
Jan-08-19 04:33PM  Editas CEO Katrine Bosley: We take the responsibility of ... CNBC Videos
04:30PM  Radius Exceeds 2018 Financial Guidance, Provides Updates Zacks
09:54AM  Alnylam (ALNY) Reports Preliminary Onpattro Revenues for Q4 Zacks
09:30AM  Has Editas Medicine (EDIT) Outpaced Other Medical Stocks This Year? Zacks
08:16AM  Editas Medicine, YY, Intel, Advanced Micro Devices and NVIDIA highlighted as Zacks Bull and Bear of the Day Zacks
06:01AM  Bull of the Day: Editas Medicine (EDIT) Zacks
Jan-07-19 04:57PM  Aerie's Rhopressa Succeeds in Study on Japanese Patients Zacks +7.46%
10:03AM  Vertex, CRISPR's Sickle Disease Drug Gets FDA's Fast Track Tag Zacks
09:00AM  Editas Medicine Reports on Recent Progress at J.P. Morgan Healthcare Conference GlobeNewswire
Jan-04-19 06:29PM  Jazz Inks Deal with Codiak to Develop Exosome Therapeutics Zacks +5.65%
04:24PM  These Stocks Pop After FDA Expedites Review Of Gene-Editing Therapy Investor's Business Daily
Jan-03-19 09:30AM  Novo Nordisk Boasts Strong Diabetes Presence and Pipeline Zacks -5.91%
09:15AM  2019 Starts Off in the Green Zacks
08:50AM  Sarepta (SRPT) Inks Deal With Aldevron for Plasmid DNA Supply Zacks
Jan-02-19 08:30AM  Editas Medicine to Present at the 37th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-28-18 10:29AM  Biotech markets could be very promising in 2019 Yahoo Finance Video
08:29AM  Horizon Pharma's Ravicti Gets FDA Nod for Expanded Age Group Zacks
Dec-21-18 04:32PM  Why Perrigo, New Age Beverages, and Editas Medicine Slumped Today Motley Fool -20.78%
11:37AM  Why Editas Medicine Is Sinking Today Motley Fool
09:00AM  Editas Medicine Announces Transition of Chief Financial Officer GlobeNewswire
Dec-18-18 10:24PM  Is Editas Medicine, Inc. (EDIT) A Good Stock To Buy? Insider Monkey
Dec-13-18 02:23PM  Edited Transcript of EDIT earnings conference call or presentation 7-Nov-18 10:00pm GMT Thomson Reuters StreetEvents
Dec-10-18 04:31PM  Why CRSP Stock Has Added Layers of Risk InvestorPlace
12:42PM  Here's Why Editas Medicine Jumped 23% in November Motley Fool
09:00AM  Editas Medicine Names Cynthia Collins to Board of Directors GlobeNewswire
Dec-09-18 11:32AM  Is Editas Medicine a Buy? Motley Fool
Dec-02-18 07:35PM  Editas Medicine Announces Pre-Clinical Data Supporting Novel Approach for Treatment of Sickle Cell Disease and Beta-Thalassemia GlobeNewswire
09:02AM  Better Buy: Editas Medicine vs. Sangamo Therapeutics Motley Fool
Nov-30-18 04:14PM  This Biotech Stock Could Launch Its First CRISPR Drug In 2022 Investor's Business Daily
10:31AM  Why Crispr Therapeutics Stock Is Up By 65% So Far in 2018 Motley Fool
10:24AM  FDA clears Editas to test gene-editing drug in humans American City Business Journals
07:30AM  Editas Medicine Announces FDA Acceptance of IND Application for EDIT-101 GlobeNewswire
Nov-26-18 02:46PM  Mass. biotech leaders voice alarm over report of first gene-edited babies American City Business Journals
Nov-12-18 08:30AM  Analysis: Positioning to Benefit within IDEXX Laboratories, Editas Medicine, Arconic, Cardtronics, Cloudera, and BMC Stock Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Nov-08-18 08:00AM  Editas Medicine Makes Steady Progress in Another Solid Quarter Motley Fool
Nov-07-18 07:46PM  Cambridge's Editas asks FDA to start gene editing trial American City Business Journals +5.69%
07:37PM  Editas Medicine, Inc. (EDIT) Q3 2018 Earnings Conference Call Transcript Motley Fool
07:10PM  Editas Medicine (EDIT) Reports Q3 Loss, Tops Revenue Estimates Zacks
06:03PM  Editas: 3Q Earnings Snapshot Associated Press
04:01PM  Editas Medicine Announces Third Quarter 2018 Results and Update GlobeNewswire
Editas Medicine, Inc. operates as a clinical stage genome editing company. The company focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary genome editing platform based on CRISPR technology to target genetically addressable diseases and therapeutic areas. The company develops EDIT-101 for Leber Congenital Amaurosis type 10, a genetic form of vision loss that leads to blindness in childhood. It also develops other therapies for eye diseases, such as Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; Retinitis Pigmentosa, a progressive form of retinal degeneration; and Herpes Simplex Virus 1 that causes lifelong infections leading to ocular and oral disease. In addition, the company develops hematopoietic stem cells for treating sickle cell disease and beta thalassemia. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; a strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and a strategic research collaboration and cross-licensing agreement with BlueRock Therapeutics to combine their respective genome editing and cell therapy technologies to discover, develop, and manufacture engineered cell medicines. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Myer VickeshChief Technology OfficerMar 18Option Exercise0.653,0001,9503,000Mar 20 04:02 PM
Myer VickeshChief Technology OfficerMar 18Sale24.503,00073,5000Mar 20 04:02 PM
Hopfield JessicaDirectorMar 05Buy23.9410,200244,18816,900Mar 07 04:02 PM
Myer VickeshChief Technology OfficerFeb 20Option Exercise0.653,0001,9503,000Feb 22 04:11 PM
Myer VickeshChief Technology OfficerFeb 20Sale20.423,00061,2600Feb 22 04:11 PM
Hack Andrew A. F.Chief Financial OfficerFeb 04Option Exercise6.486,89544,6806,895Feb 06 04:41 PM
Hack Andrew A. F.Chief Financial OfficerFeb 04Sale21.396,895147,4840Feb 06 04:41 PM
Myer VickeshChief Technology OfficerJan 18Option Exercise11.214,00044,8404,000Jan 18 08:58 PM
Myer VickeshChief Technology OfficerJan 18Sale26.504,000106,0000Jan 18 08:58 PM
Myer VickeshChief Technology OfficerJan 17Option Exercise0.653,0001,9503,000Jan 18 08:58 PM
Myer VickeshChief Technology OfficerJan 17Sale26.183,00078,5400Jan 18 08:58 PM
Bosley KatrinePresident and CEOJan 08Sale25.2712,000303,2401,204,966Jan 10 04:11 PM
Hack Andrew A. F.Chief Financial OfficerJan 04Option Exercise6.487,00045,3607,000Jan 08 05:36 PM
Hack Andrew A. F.Chief Financial OfficerJan 04Sale22.487,000157,3600Jan 08 05:36 PM
Myer VickeshChief Technology OfficerDec 18Option Exercise11.214,00044,8404,000Dec 19 04:41 PM
Myer VickeshChief Technology OfficerDec 18Sale27.414,000109,6400Dec 19 04:41 PM
Myer VickeshChief Technology OfficerDec 17Option Exercise0.653,0001,9503,000Dec 19 04:41 PM
Myer VickeshChief Technology OfficerDec 17Sale27.893,00083,6630Dec 19 04:41 PM
Bosley KatrinePresident and CEODec 03Sale31.9212,000383,0871,216,966Dec 06 04:02 PM
Hack Andrew A. F.Chief Financial OfficerNov 23Option Exercise6.485,28434,2405,284Nov 27 04:25 PM
Hack Andrew A. F.Chief Financial OfficerNov 23Sale28.155,284148,7390Nov 27 04:25 PM
Myer VickeshChief Technology OfficerNov 20Option Exercise11.214,00044,8404,000Nov 21 04:03 PM
Myer VickeshChief Technology OfficerNov 20Sale26.504,000106,0000Nov 21 04:03 PM
Myer VickeshChief Technology OfficerNov 19Option Exercise0.653,0001,9502,700Nov 21 04:03 PM
Myer VickeshChief Technology OfficerNov 19Sale28.193,00084,5790Nov 21 04:03 PM
Bosley KatrinePresident and CEONov 01Sale26.8812,000322,5081,228,966Nov 05 05:42 PM
Hack Andrew A. F.Chief Financial OfficerOct 26Option Exercise6.486,00038,8806,000Oct 30 05:05 PM
Hack Andrew A. F.Chief Financial OfficerOct 26Sale25.706,000154,2000Oct 30 05:05 PM
Myer VickeshChief Technology OfficerOct 18Option Exercise11.214,00044,8404,000Oct 19 04:01 PM
Myer VickeshChief Technology OfficerOct 18Sale29.444,000117,7600Oct 19 04:01 PM
Myer VickeshChief Technology OfficerOct 17Option Exercise0.653,0001,9503,000Oct 19 04:01 PM
Myer VickeshChief Technology OfficerOct 17Sale28.873,00086,6100Oct 19 04:01 PM
Bosley KatrinePresident and CEOOct 01Sale31.0212,000372,2931,240,966Oct 03 04:03 PM
Hack Andrew A. F.Chief Financial OfficerSep 28Option Exercise6.488,00051,8408,000Oct 02 04:02 PM
Hack Andrew A. F.Chief Financial OfficerSep 28Sale32.088,000256,6400Oct 02 04:02 PM
Myer VickeshChief Technology OfficerSep 18Option Exercise11.214,00044,8404,000Sep 19 04:03 PM
Myer VickeshChief Technology OfficerSep 18Sale32.194,000128,7600Sep 19 04:03 PM
Myer VickeshChief Technology OfficerSep 17Option Exercise0.653,0001,9503,000Sep 19 04:03 PM
Myer VickeshChief Technology OfficerSep 17Sale32.333,00096,9900Sep 19 04:03 PM
Bosley KatrinePresident and CEOSep 04Sale32.3512,000388,2101,252,966Sep 06 04:02 PM
Hack Andrew A. F.Chief Financial OfficerAug 31Option Exercise6.4810,00064,80010,000Sep 05 04:04 PM
Hack Andrew A. F.Chief Financial OfficerAug 31Sale32.2310,000322,3000Sep 05 04:04 PM
Myer VickeshChief Technology OfficerAug 20Option Exercise11.214,00044,8403,600Aug 21 04:09 PM
Bosley KatrinePresident and CEOAug 20Sale30.1712,000362,0081,264,966Aug 22 04:16 PM
Myer VickeshChief Technology OfficerAug 20Sale29.874,000119,4800Aug 21 04:09 PM
Myer VickeshChief Technology OfficerAug 17Option Exercise0.653,0001,9503,000Aug 21 04:09 PM
Myer VickeshChief Technology OfficerAug 17Sale29.653,00088,9500Aug 21 04:09 PM
Bosley KatrinePresident and CEOAug 01Sale29.558,333246,2531,276,966Aug 03 04:01 PM
Myer VickeshChief Technology OfficerJul 18Option Exercise11.217,00078,4706,150Jul 19 04:07 PM
Myer VickeshChief Technology OfficerJul 18Sale35.567,000248,8920Jul 19 04:07 PM
Myer VickeshChief Technology OfficerJul 17Option Exercise0.657,0004,5504,000Jul 19 04:07 PM
Myer VickeshChief Technology OfficerJul 17Sale35.717,000249,9800Jul 19 04:07 PM
Bosley KatrinePresident and CEOJul 02Sale36.298,333302,4411,285,299Jul 05 04:00 PM
Myer VickeshChief Technology OfficerJun 19Option Exercise11.217,00078,4707,000Jun 20 04:57 PM
Myer VickeshChief Technology OfficerJun 19Sale38.397,000268,7300Jun 20 04:57 PM
Myer VickeshChief Technology OfficerJun 18Option Exercise0.657,0004,5504,300Jun 20 04:57 PM
Myer VickeshChief Technology OfficerJun 18Sale38.127,000266,8420Jun 20 04:57 PM
Albright CharlesChief Scientific OfficerJun 13Option Exercise16.5110,000165,10010,000Jun 15 04:16 PM
Albright CharlesChief Scientific OfficerJun 13Sale35.9810,000359,8000Jun 15 04:16 PM
Hack Andrew A. F.Chief Financial OfficerJun 04Option Exercise24.603,00073,8003,000Jun 05 04:08 PM
Hack Andrew A. F.Chief Financial OfficerJun 04Sale37.103,000111,3000Jun 05 04:08 PM
Hack Andrew A. F.Chief Financial OfficerJun 01Option Exercise6.487,00045,3605,000Jun 05 04:08 PM
Hack Andrew A. F.Chief Financial OfficerJun 01Sale39.287,000274,9700Jun 05 04:08 PM
Bosley KatrinePresident and CEOJun 01Sale37.558,333312,8731,293,632Jun 05 04:06 PM
Albright CharlesChief Scientific OfficerMay 23Option Exercise16.5110,000165,10010,000May 25 04:31 PM
Albright CharlesChief Scientific OfficerMay 23Sale35.0010,000350,0000May 25 04:31 PM
MULLEN JAMES CDirectorMay 18Buy38.0310,000380,25210,000May 22 05:28 PM
Hopfield JessicaDirectorMay 17Buy37.286,700249,7806,700May 21 04:27 PM
Bosley KatrinePresident and CEOMay 01Sale31.958,333266,2391,301,965May 03 05:31 PM